[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  $amgns Amgen's marketing application for Imdelltra in China has been accepted. This news is driving positive sentiment and engagement on social media. ### About $amgns A cryptocurrency or stock ticker symbol. ### Engagements: XX [#](/topic/$amgns/interactions) ---  [Engagements 24-Hour Chart Data](/topic/$amgns/time-series/interactions.tsv) **Current Value**: XX **Daily Average**: XXX **1 Month**: XXXXXX +900% **1-Year High**: XXXXXX on 2025-06-24 **1-Year Low**: X on 2025-05-04 | Social Network | X | | -------------- | - | | Engagements | XX | ### Mentions: X [#](/topic/$amgns/posts_active) ---  [Mentions 24-Hour Chart Data](/topic/$amgns/time-series/posts_active.tsv) **Current Value**: X **Daily Average**: X **1 Week**: X -XX% **1 Month**: X +17% **1-Year High**: X on 2025-06-24 **1-Year Low**: X on 2025-04-28 | Social Network | X | | -------------- | - | | Mentions | X | ### Creators: X [#](/topic/$amgns/contributors_active) ---  [Creators 24-Hour Chart Data](/topic/$amgns/time-series/contributors_active.tsv) X unique social accounts have posts mentioning $amgns in the last XX hours which is no change from in the previous XX hours **Daily Average**: X **1 Week**: X -XX% **1 Month**: X no change **1-Year High**: X on 2025-06-23 **1-Year Low**: X on 2025-04-28 **Top assets mentioned** In the posts about $amgns in the last XX hours [One Cash (ONC)](/topic/$onc) **Top topics mentioned** In the posts about $amgns in the last XX hours [china](/topic/china), [$onc](/topic/$onc), [coins stablecoin](/topic/coins-stablecoin) ### Top Social Posts [#](/topic/$amgns/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "$ONC and $AMGN's marketing application to #China #NMPA for Imdelltra (tarlatamab) has been accepted. The drug was previously granted priority review for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have failed at least two prior lines of therapy including platinum-based chemotherapy. Tarlatamab is a first-in-class CD3/DLL3 bispecific antibody developed by Amgen" [@chuminhua432](/creator/x/chuminhua432) on [X](/post/tweet/1945755163702202835) 2025-07-17 07:59:16 UTC 2455 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Amgen's marketing application for Imdelltra in China has been accepted. This news is driving positive sentiment and engagement on social media.
A cryptocurrency or stock ticker symbol.
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXX
1 Month: XXXXXX +900%
1-Year High: XXXXXX on 2025-06-24
1-Year Low: X on 2025-05-04
Social Network | X |
---|---|
Engagements | XX |
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X -XX%
1 Month: X +17%
1-Year High: X on 2025-06-24
1-Year Low: X on 2025-04-28
Social Network | X |
---|---|
Mentions | X |
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $amgns in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1 Week: X -XX%
1 Month: X no change
1-Year High: X on 2025-06-23
1-Year Low: X on 2025-04-28
Top assets mentioned In the posts about $amgns in the last XX hours
Top topics mentioned In the posts about $amgns in the last XX hours
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$ONC and $AMGN's marketing application to #China #NMPA for Imdelltra (tarlatamab) has been accepted. The drug was previously granted priority review for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have failed at least two prior lines of therapy including platinum-based chemotherapy. Tarlatamab is a first-in-class CD3/DLL3 bispecific antibody developed by Amgen"
@chuminhua432 on X 2025-07-17 07:59:16 UTC 2455 followers, XXX engagements
/topic/$amgns